Floseal Treatment for Posterior Epistaxis Study

Ottawa Hospital Research Institute

Status: Completed

Conditions: Epistaxis

Treatments: Drug: Floseal

Study type: Interventional

Funder types: Other

Identifiers

NCT01098578

REB 2009428-01H (Other Identifier)

Baxter BS09-000313

Details and patient eligibility

About

Effectiveness of Floseal for the treatment of posterior epistaxis.

Full description

Floseal, a hemostatic agent, is an effective treatment for anterior epistaxis as well as numerous other acute bleeding conditions throughout the body. The investigators hypothesize that Floseal is an effective treatment for posterior epistaxis. If so, then this will also lead to significant cost savings in comparison to any other method of treatment of posterior epistaxis. The investigators have planned a prospective, nonblinded, nonrandomised study with a total of 40 subjects with posterior epistaxis to be included in this study.

Enrollment: 20 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age greater than 18 years of age
• posterior epistaxis

Exclusion criteria

• patients with anterior epistaxis
• known sensitivity to any of the materials of Floseal or the topical medications administered as part of the evaluation and treatment of epistaxis (lidocaine, xylometazoline hydrochloride)
• pregnant or breast feeding woman

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

Floseal

Experimental group

Description:

Received 1 syringe of Floseal for treatment of posterior epistaxis.

Treatment:

Drug: Floseal